Acitretin fulfills a unique role in the strategies used to treat psoriasis because its mechanism of action is different from that of other systemic drugs. Psoriasis Area and Severity Index (PASI) was first used to assess the efficacy of the new retinoid in clinical trials. FDA-approved treatments for moderate to severe psoriasis, which affects approximately 33 of psoriasis patients,2 have burgeoned since 2003, when only acitretin, cyclosporine, methotrexate, and phototherapy were available. 7 FDA-approved treatments for moderate to severe psoriasis, which affects approximately 33 of psoriasis patients,2 have burgeoned since 2003, when only acitretin, cyclosporine, methotrexate, and phototherapy were available. THE COMBINATION of phototherapy with retinoids has been shown to be advantageous over either therapy alone in the treatment of moderate to severe psoriasis.
Treatment options for moderate to severe psoriasis include topical and systemic medications, phototherapy, and excimer laser, Combination therapies are often more effective than one treatment alone. Combining vitamin D ointments with systemic medicines, notably methotrexate, acitretin, or cyclosporine, increases its effectiveness. To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients. We aimed to compare the efficacy and safety of TwHF compared with acitretin in the treatment of moderate to severe psoriasis vulgaris.
Biological therapies of proven benefit in severe psoriasis include etanercept, adalimumab and infliximab, which target tumour necrosis factor. Only around a third of patients with chronic plaque psoriasis achieve and maintain good disease control when acitretin is used as monotherapy although its efficacy in pustular and erythrodermic psoriasis is higher. Severe plaque type psoriasis: The efficacy of acitretin in chronic plaque psoriasis as a monotherapy is below methotrexate and cyclosporine. Soriatane (acitretin) is used for moderate to severe psoriasis. Soriatane can reduce the effectiveness of phenytoin, a common drug for epilepsy, when given at the same time.
Low-Dose Regimens of Soriatane(R) (Acitretin) Effective in the Treatment of Moderate-to-Severe Plaque-Type Psoriasis; New Data Presented at AAD Shows Lower Doses of Soriatane Are Effective as Maintenance Therapy and Well-Tolerated.